Emerging treatments
Intravitreal sirolimus
Offers several potential advantages over existing approved treatments for non-infectious uveitis, and is currently undergoing clinical trials. It is a mammalian target of rapamycin (mTOR) inhibitor with immunosuppressant properties. It avoids ocular complications such as cataracts associated with corticosteroid treatment, and can be injected using a smaller gauge needle. Phase II trials have shown that it is effective in controlling uveitis and reducing macular oedema due to diabetic retinopathy.[44]
Tocilizumab
Tocilizumab is a humanised monoclonal antibody directed against interleukin-6. This medication is helpful in the management of systemic juvenile idiopathic arthritis, but its role in associated uveitis remains less established.[45] At present, it may be considered as an adjunctive therapy in cases of non-infectious uveitis refractory to tumour necrosis factor-alpha inhibitors.[37][46]
Use of this content is subject to our disclaimer